Chinese Scientists Achieve World's First Diabetes Cure Using Cell Therapy: Report
Chinese Scientists Achieve World's First Diabetes Cure Using Cell Therapy: Report
A team of Chinese scientists has successfully cured a patient's diabetes using cell therapy, marking a global first.
一組中國科學家使用細胞療法成功治癒了患者的糖尿病，這標誌着全球首例。
What Happened: The patient, who was at high risk of severe diabetes complications, has been insulin-free for 33 months following the treatment, reported the South China Morning Post. The research, led by Yin Hao of Shanghai Changzheng Hospital, was published in the journal Cell Discovery on Apr. 30.
發生了什麼：據《南華早報》報道，該患者出現嚴重糖尿病併發症的風險很高，治療後已有33個月沒有胰島素。這項由上海長征醫院尹浩領導的研究於4月30日發表在《細胞發現》雜誌上。
Yin said that the patient's pancreatic islet function was effectively restored, thanks to the innovative approach. The team used the patient's own peripheral blood mononuclear cells, which were reprogrammed into "seed cells" and then used to regenerate pancreatic islet tissue in a controlled environment.
尹說，得益於這種創新的方法，患者的胰島功能得到了有效恢復。研究小組使用了患者自己的外周血單核細胞，這些細胞被重新編程爲 “種子細胞”，然後在受控的環境中用於胰腺胰島組織再生。
"I think this study represents an important advance in the field of cell therapy for diabetes," Timothy Kieffer, a professor in the Department of Cellular and Physiological Sciences at the University of British Columbia in Canada said.
加拿大不列顛哥倫比亞大學細胞與生理科學系教授蒂莫西·基弗說：“我認爲這項研究代表了糖尿病細胞療法領域的一項重要進展。”
'
'
Why It Matters: Diabetes is a chronic condition that affects the body's ability to convert food into energy. The breakthrough in cell therapy offers hope for the millions of people worldwide who suffer from this disease. The treatment could potentially prevent serious complications such as heart disease, vision loss, and kidney disease, which are common in diabetic patients.
爲何重要：糖尿病是一種慢性疾病，會影響人體將食物轉化爲能量的能力。細胞療法的突破爲全球數百萬患有這種疾病的人帶來了希望。這種治療有可能預防嚴重的併發症，例如心臟病、視力喪失和腎臟疾病，這些併發症在糖尿病患者中很常見。
Yin's research is particularly significant for China, where a quarter of the global diabetic population resides, placing a significant strain on the country's healthcare system. The successful treatment of this patient could pave the way for more extensive studies and potentially revolutionize diabetes treatment worldwide.
尹的研究對中國尤其重要，中國有四分之一的糖尿病患者居住在中國，這給該國的醫療體系帶來了巨大壓力。該患者的成功治療可能爲更廣泛的研究鋪平道路，並有可能徹底改變全球糖尿病的治療方式。
The success of this cell therapy treatment in China comes at a time when the global diabetes market is undergoing significant changes. Companies like Eli Lilly and Co are exploring new insulin dosing options, while Novo Nordisk is facing supply chain challenges for its popular diabetes drug, Ozempic, in Germany.
這種細胞療法在中國取得成功的時候正值全球糖尿病市場正在發生重大變化。禮來等公司正在探索新的胰島素劑量選擇，而諾和諾德則因其在德國廣受歡迎的糖尿病藥物Ozempic而面臨供應鏈挑戰。
Image Via Shutterstock
圖片來自 Shutterstock
This story was generated using Benzinga Neuro and edited by Kaustubh Bagalkote
這個故事是使用 Benzinga Neuro 創作的，由 Kaustubh Bagalkote
譯文內容由第三人軟體翻譯。